De Novo Drug Design of Potential Inhibitors of SARS-CoV-2 Papain-like Protease

De Novo Drug Design of Potential Inhibitors of SARS-CoV-2 Papain-like Protease

Here, potential inhibitors of the SARS-CoV-2 papain-like protease (PL<sup>pro</sup>) are reported. A drug molecule (PL<sup>pro</sup>-50), designed de novo using generative neural networks, interacts with PL<sup>pro</sup> via hydrogen bonding, forming a salt bridge...

Full description

Bibliographic Details
Main Author:	Edgar Clyde R. Lopez
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Medical Sciences Forum
Subjects:	SARS-CoV-2 COVID-19 de novo drug design molecular dynamics
Online Access:	https://www.mdpi.com/2673-9992/21/1/37

Similar Items

De Novo Drug Design of Potential Inhibitors of the Receptor-Binding Domain of SARS-CoV-2 Variants
by: Edgar Clyde R. Lopez
Published: (2023-04-01)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
by: Tien Huynh, et al.
Published: (2021-02-01)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
by: Pietro Delre, et al.
Published: (2020-11-01)

Molecular Docking Study of Nigella sativa Alkaloid Compounds as the Inhibitor of Papain-Like Protease SARS-CoV-2
by: Gusnia Meilin Gholam, et al.
Published: (2023-06-01)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**
by: Dr. Milan Sencanski, et al.
Published: (2022-02-01)

Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study
by: Ahmad Alzamami, et al.
Published: (2022-04-01)

Identification of potential SARS-CoV-2 papain-like protease inhibitors with the ability to interact with the catalytic triad
by: Murtala Muhammad, et al.
Published: (2023-01-01)

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
by: Khushboo Bafna, et al.
Published: (2021-05-01)

Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
by: Dakshinamurthy Sivakumar, et al.
Published: (2021-05-01)

Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations
by: Jamie Holmes, et al.
Published: (2024-05-01)

Crystal structure of SARS-CoV-2 papain-like protease
by: Xiaopan Gao, et al.
Published: (2021-01-01)

Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach
by: Eslam B. Elkaeed, et al.
Published: (2022-09-01)

Mechanistic Insights into Targeting SARS-CoV-2 Papain-like Protease in the Evolution and Management of COVID-19
by: Nonjabulo Ntombikhona Magwaza, et al.
Published: (2024-09-01)

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone
by: Haihai Jiang, et al.
Published: (2022-02-01)

Insights into the Dynamics and Binding of Two Polyprotein Substrate Cleavage Points in the Context of the SARS-CoV-2 Main and Papain-like Proteases
by: Zainab Kemi Sanusi, et al.
Published: (2022-11-01)

Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids
by: Neelaveni Thangavel, et al.
Published: (2023-01-01)

Insights for Future Pharmacology: Exploring Phytochemicals as Potential Inhibitors Targeting SARS-CoV-2 Papain-like Protease
by: Jawaria Jabeen, et al.
Published: (2024-08-01)

Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors
by: Marjorie C. L. C. Freire, et al.
Published: (2021-08-01)

Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes
by: Jinlin Tan, et al.
Published: (2022-09-01)

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity
by: Anasha Kawall, et al.
Published: (2023-01-01)

Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking
by: Jorge Luis Valdés-Albuernes, et al.
Published: (2024-03-01)

Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity Assay
by: Eleni Pitsillou, et al.
Published: (2020-12-01)

Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro
by: Maximilian Große, et al.
Published: (2022-06-01)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease
by: Zou Zhihui, et al.
Published: (2022-07-01)

Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice
by: Mianling Yang, et al.
Published: (2024-09-01)

Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors
by: Neelaveni Thangavel, et al.
Published: (2022-12-01)

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2
by: Habibu Tijjani, et al.
Published: (2022-09-01)

Search for Novel Potent Inhibitors of the SARS-CoV-2 Papain-like Enzyme: A Computational Biochemistry Approach
by: Manuel I. Osorio, et al.
Published: (2022-08-01)

In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2
by: Kunal Bhattacharya, et al.
Published: (2022-03-01)

Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PL<sup>pro</sup>) Inhibitor
by: Sebastjan Kralj, et al.
Published: (2024-01-01)

An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease
by: Subodh Kumar Samrat, et al.
Published: (2024-08-01)

9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2
by: Kabita Pandey, et al.
Published: (2025-02-01)

Deciphering the Molecular Interaction Process of Gallium Maltolate on SARS-CoV-2 Main and Papain-Like Proteases: A Theoretical Study
by: Kevin Taype-Huanca, et al.
Published: (2024-04-01)

De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning
by: Marcos V. S. Santana, et al.
Published: (2021-02-01)

Hydrazones and Thiosemicarbazones Targeting Protein-Protein-Interactions of SARS-CoV-2 Papain-like Protease
by: Wiebke Ewert, et al.
Published: (2022-04-01)

Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking
by: Luis Castillo-Campos, et al.
Published: (2023-06-01)

Flavonoids Derived from the Roots of <i>Lespedeza bicolor</i> Inhibit the Activity of SARS-CoV Papain-like Protease
by: Hyun Sim Woo, et al.
Published: (2024-11-01)

Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner
by: Xiang-Hong Ran, et al.
Published: (2022-08-01)

Bilastine Based Drugs as SARS-CoV-2 Protease Inhibitors: Molecular Docking, Dynamics, and ADMET Related Studies
by: Ajoy Kumer, et al.
Published: (2022-04-01)

Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MPRO enzymes of SARS-CoV-2
by: Shaibu Oricha Bello, et al.
Published: (2023-11-01)